| Literature DB >> 28243287 |
Maryam Niyyati1, Samira Dodangeh1, Jacob Lorenzo-Morales2.
Abstract
Acanthamoeba keratitis (AK) is a sight-threating infection of the cornea that mostly affects contact lens wearers. Until now, AK treatment remains very difficult due to the existence of a highly resistant cyst stage in the life cycle of Acanthamoeba which is extremely resistant to most of the available anti-amoebic compounds. Moreover, current treatment of AK is usually based in the combination of various therapeutic agents such as polyhexamethylene biguanide or chlorhexidine and propamidine isethionate. However, all the mentioned compounds have also showed toxic side effects on human keratocytes and presented poor cysticidal effect at the concentrations currently used in the established AK treatments. Nowadays, the elucidation of novel compounds with antimicrobial and anticancer properties from plant and herbs with medicinal properties have encouraged researchers to evaluate plants as a source of new molecules with anti-trophozoite and cysticidal effects. Thus, in recent years, many natural products have been reported to present potent anti-Acanthamoeba properties with good selectivity and minimal toxic effects. Therefore, the chemical drugs currently used for AK treatment, their drawbacks as well as the current research in medicinal plants as a source of potent anti-Acanthamoeba compounds are described in this review.Entities:
Keywords: Acanthamoeba infections; Chemical therapy; Medicinal plant
Year: 2016 PMID: 28243287 PMCID: PMC5316269
Source DB: PubMed Journal: Iran J Pharm Res ISSN: 1726-6882 Impact factor: 1.696
Characteristics of Acanthamoeba spp. as an agents of amoebic encephalitis and amoebic keratitis (Visvesvara et al, 2007).
|
| ||
|---|---|---|
|
|
| |
| Morphological Features | Trophozoite: Vesicular nucleus; spine-like pseudopodia projecting from surface; cyst: | |
|
| Axenic, bacterized, and defined media; tissue culture cells; growth at 37 °C (CNS isolates) or 30 °C (keratitis isolates) | |
| The most important diseases |
|
|
| Incubation period | Weeks to months (GAE) | Days (AK) |
| High risk people | Typically | Mainly contact-lens wearers; Low |
| Clinical Characteristics | Headache, fever, nausea, vomiting, behavioral changes, stiff neck, lethargy, loss of consciousness, seizures, coma, and death (GAE) | Painful, sight- redness, photophobia, |
| Clinical course | Sub-acute course; | Penetration of amoebae into cornea; |
| Laboratory diagnostic methods | Amoeba seen in CSF; Molecular method | Not relevant (AK) |
| Neuroimaging (CT and/or MRI) | Presence of space occupying or ring | Corneal scrapings or biopsy; |
| Prevention | Monitoring of environmental sources such as waters, ventilators, air conditioning units (GAE) | Use of anti-acanthamoeba lens solutions; avoiding swimming or bathing with contact |
| Chemical therapy | Combination of drugs such as ketoconazole, fluconazole, itraconazole, azithromycin, sulfadiazine, amphotericin B, rifampin, voriconazole, and miltefosine (GAE) | Combination chemotherapeutic agents such as polyhexamethylene biguanide, chlorhexidine (AK) |
| Prognosis | Poor; diagnosis is often Post-mortem, only | Good with early diagnosis and proper treatment (AK) |
Several medicinal plants with reported activity against Acanthamoeba spp
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|
|
| Methanol | 32 mg/mL | 3 h | 0 | 32 mg/mL | 12 h | 0 |
|
| Methanol | 32 mg/mL | 24 h | 0 | 32 mg/mL | 72 h | 53/07 |
|
| Methanol | 32 mg/mL | 72 h | 55/07 | 32 mg/ mL | 72 h | 70/0 |
|
| Chloroformic | 10 mg/mL | 48 h | 0 | 10 mg/mL | 72 h | 0 |
|
| Methanol | 32 mg/mL | 3 h | 0 | 32 mg/mL | 24 h | 0 |
|
| Ethyl acetate | N/A | N/A | N/A | 500 mg/mL | 72 h | 25 |
|
| Ethanol | N/A | N/A | N/A | 100 mg/mL (MIC | 24 h | 0 |
|
| Ethanol | N/A | N/A | N/A | 1 g/ml (MIC) | 48 h | 0 |
|
| Ethanol | N/A | N/A | N/A | 200 mg/mL (MIC) | 72 h | 0 |
|
| Aqueous | 32 mg/mL | 24 h | 0 | 32 mg/mL | 72 h | 74/7 |
N/A= Not Applicable
MIC= Minimum Inhibitory Concentration.